Anebulo Pharmaceuticals (NASDAQ:ANEB) and Argos Therapeutics (OTCMKTS:ARGSQ) Head-To-Head Analysis

Anebulo Pharmaceuticals (NASDAQ:ANEB) and Argos Therapeutics (OTCMKTS:ARGSQ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Profitability

This table compares Anebulo Pharmaceuticals and Argos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-109.40%	-98.40%
Argos Therapeutics	N/A	N/A	N/A

Insider & Institutional Ownership

28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 85.9% of Anebulo Pharmaceuticals shares are held by insiders. Comparatively, 28.2% of Argos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for Anebulo Pharmaceuticals and Argos Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	0	0	3	0	3.00
Argos Therapeutics	0	0	0	0	N/A

Anebulo Pharmaceuticals presently has a consensus price target of $6.67, indicating a potential upside of 119.30%. Given Anebulo Pharmaceuticals’ higher possible upside, equities research analysts clearly believe Anebulo Pharmaceuticals is more favorable than Argos Therapeutics.

Earnings & Valuation

This table compares Anebulo Pharmaceuticals and Argos Therapeutics’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$11.73 million	($0.42)	-7.24
Argos Therapeutics	$1.90 million	0.30	-$40.57 million	N/A	N/A

Anebulo Pharmaceuticals has higher earnings, but lower revenue than Argos Therapeutics.

Volatility and Risk

Anebulo Pharmaceuticals has a beta of -0.98, indicating that its share price is 198% less volatile than the S&P 500. Comparatively, Argos Therapeutics has a beta of 2.47, indicating that its share price is 147% more volatile than the S&P 500.

Summary

Anebulo Pharmaceuticals beats Argos Therapeutics on 5 of the 9 factors compared between the two stocks.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

About Argos Therapeutics

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.